Quest Diagnostics Incorporated (DGX) Stock Score, Valuation & Financial Research
Quest Diagnostics Incorporated is in the Healthcare sector and Medical - Diagnostics & Research industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 36/100.
Quick answer for DGX
Quest Diagnostics Incorporated currently has a Wall Street Score of 36/100. The stored market price is $248.03. Its financial score is 29/100. Its valuation score is 16/100. The latest WSS change is -0.3 points. These figures are a research snapshot, not a buy or sell recommendation.
What Quest Diagnostics Incorporated does
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call
DGX financial snapshot
- Wall Street Score:
- 36/100
- Current price:
- $248.03
- Market capitalization:
- $27.38B
- Revenue:
- $11.56B
- Net income:
- $1.06B
- Free cash flow:
- $1.36B
- Cash:
- $626.0M
- Total debt:
- $6.38B
- EPS:
- 9.54
- P/E ratio:
- 26.0x
- Financial score:
- 29/100
- Valuation score:
- 16/100
- Revenue score:
- 24/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $1.36B, showing positive cash generation.
- The balance sheet shows $626.0M of cash versus $6.38B of total debt, so leverage deserves attention.
- The latest Wall Street Score change is -0.3 points: DGX decreased 0.3 points because Capital declined by 2 points.
What the numbers mean
Its current valuation score is 16/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 29/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-17.
How to research DGX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.